Drug Interaction:
Reports not available.
Indication:
Anovolutory infertility .
Hypogonadotrophic hypogonadism in males and females
Follicle stimulation in IVF
Adverse Reaction:
Sensitivity reactions
Ovarian enlargement or cysts or rupture
Hyperstimulation presenting as renal failure, hypovalaemic shock, arterial thromboem-
Multiple pregnancies.
Abdominal pain
GI upset
Hemopritoneum
Contra-Indications:
Pregnancy,
Primary ovarian failure
Uncontrolled abnormal vaginal bleeding
Ovarian cysts or enlargement
Special precautions:
Patients with endocrine disorders or intracranial lesions, must be treated before therapy
Perform skin tests before treatment in susceptible patients
Do not complete gynacological and endocrinological exam. first
Monitor appropiate lab values
Discontinue if estrogen values or other evidence of ovarian hyperstimulation syndrome OHSS occur
If ovaries are enlarged on last day of theapy do not administer hCG, this decreases the risk of OHSS
Thromboembolic disorders
Lactation
Dosages/ Overdosage Etc:
Anovolutory infertility .
Hypogonadotrophic hypogonadism in males and females
Follicle stimulation in IVF
Initial dosage-
Initial IM dose is 75IU FSH /75 IU LH ( 1 amp /day for 7 to 12 days , follow by 10,000 IU HCG 1 day
after the last dose of menotropins
Do not exceed 12 days of menotropins admin. Test the patient until indices of oestrogenic activity
are equal to are greater than those of normal individual
Repeat dosage- If there is evidence of ovulation, but no pregnancy, repeat the regimen for at least
2 more courses before increasing the dose to 150IU FSH/150 IU LH ( 2 amp ) per day for 7 to 12 days
Patient Information:
Ref - USP PDI Vol II 17th Edition (1997)
1.Allergies-
Tell your doctor if you have ever had any unusual or allergic reaction to
menotropins. Also tell your healthcare care professional if you are allergic
to any other substances such as foods. preservatives or dyes.
2.Pregnancy-
If you become pregnant, while taking this medicine there is an increased chance of a
multiple pregnancy.
3. Other medicines-
Tell your doctor if you are using any other prescription or
non-prescription (Over-the counter) OTC medicine.
4. Other medical problems-
Make sure you tell your doctor if you have any other medical problems
especially-
Cyst on ovary- menotropin can cause further growth of cysts on the ovary
Unusual vaginal bleeding - some irregular bleeding is a sign that the
endometrium is growing too rapdily, possibly of endometric cancer, or
some hormonal inbalances, the increases in estrogen production
caused by menotropins can make these problems worse.
If a normal imbalance is present it should be treated before the beginning
of menotroins therapy
Pharmacology/ Pharmacokinetics:
Ref- Drug Facts And comparisons(2010)
Pharmacology:
Produces ovarian follicular growth in women who do not have primary ovarian failure.
In men, menotropin administered concomittantly with HCG for atleast 3 months induces
spermatogenesis with primary or secondary pituitary hypofunction who have acheived adequate masculinasation with prior HCG therapy.
Pharmacokinetics-
A Study 2000 -03 asscssed single and multiple doses of menotroins administerered
subcutaneously and IM in 3-phase , cross over design in 33 healthy, premenoausal
women who had undergone pituitary suppression .
The primary pharmacokinetics and points were FSH AUC and Cmax values. The results
are summarised-
Mean (+/- SD ) FSH pharmacokinetic Parameters
Following Menotropins Administration study (2000-03)
Pharmacokinetic single dose Multiple dose
Parameters (225 units (225units x 1 day, then
150 units x 6 days)
SC IM SC IM
Cmax milliunits/mL 8.5(2.5) 7.8(2.4) 15(3.6) 12.5(2.3)
Tmax (h) 17.9(5.8) 27.5(25.4) 8(3) 9(7)
AUC millunits*h/mL 726.2(243) 656.1(233.7) 622.7(153) 546.2(91.2)
Interaction with Food:
Reports not available
Pregnancy and lactation:
Contraindicated for use during pregnancy and lactation Observe caution
Manufacturer Details